Dynavax Technologies beats Q2 revenue expectations
Overview
Dynavax Q2 revenue rises 29%, beating analyst expectations, per LSEG data
HEPLISAV-B achieves record net product revenue of $92 mln, up 31% yr/yr
Co refines full-year HEPLISAV-B revenue guidance to $315-$325 mln
Outlook
Dynavax raises 2025 HEPLISAV-B revenue guidance to $315-$325 mln
Company expects U.S. hepatitis B vaccine market to exceed $900 mln by 2030
HEPLISAV-B to achieve at least 60% U.S. market share by 2030
Company anticipates reporting shingles vaccine trial results in August 2025
Result Drivers
HEPLISAV-B SALES - Record quarterly net product revenue of $91.9 mln, driven by increased market share in U.S. adult hepatitis B vaccine market
MARKET SHARE GAIN - HEPLISAV-B U.S. market share increased to approximately 45%, up from 42% year-ago
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $95.44 mln | $86.70 mln (4 Analysts) |
Q2 EPS | $0.16 | ||
Q2 Net Income | $18.72 mln | ||
Q2 Operating Expenses | $81.01 mln | ||
Q2 Operating Income | $14.43 mln | ||
Q2 Pretax Profit | $21.22 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Dynavax Technologies Corp is $25.00, about 55.2% above its August 6 closing price of $11.19
The stock recently traded at 87 times the next 12-month earnings vs. a P/E of 27 three months ago
Press Release:
